ENTITY
Scilex

Scilex (SCLX US)

12
Analysis
Health Care • United States
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido® for postherpetic neuralgia, ELYXYB® for migraine, and GLOPERBA® for gout flares. The company is headquartered in Palo Alto, California, and was founded in 2019.
more
bullish•Scilex
•22 Mar 2022 11:36•Syndicated

The SPAC Week in Review

Vickers Vantage Corp. I (VCKA) & Scilex Holding Company (a subsidiary of Sorrento Therapeutics) (Valuation: $440M EV). Pono Capital Corp (PONO) &...

Logo
454 Views
Share
bullish•Scilex
•07 Dec 2021 12:00•Syndicated

The Nightcap from SPAC Track

Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (VCKA) Enter into Letter of Intent for Proposed...

Logo
358 Views
Share
x